Screener
Bicara Therapeutics BCAX CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033429
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net cash used in operating activities | (37,508) | (28,106) |
| Investing activities: | ||
| Proceeds from maturities and sales of marketable securities | 101,000 | — |
| Purchase of property and equipment | (60) | — |
| Net cash provided by investing activities | 100,940 | — |
| Financing activities: | ||
| Proceeds from issuance on common stock and accompanying pre-funded warrants, net of issuance costs | 161,763 | — |
| Proceeds from exercise of options | 1,582 | 460 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bicara Therapeutics's capex?
- Bicara Therapeutics (BCAX) reported capex of $60K in Q1 2026.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Bicara Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude